Business Standard

Lupin rebounds 5% from 52-week low on drug launch

The stock up 4% to Rs 1,086, bouncing back 5% from 52-wk low of Rs 1,036 hit in intra-day trade

Lupin Pharma
Premium

SI Reporter Mumbai
Lupin moved higher by 4% to Rs 1,086, bouncing back 5% from intra-day low on National Stock Exchange (NSE), after the company said it has launched in the US market its generic version of Moxifloxacin Hydrochloride Ophthalmic solution used for treating bacterial conjunctivitis.

The stock hit a 52-week low of Rs 1,036 on NSE in intra-day trade. At 01:22 pm; it was up 3.7% at Rs 1,082, as compared to 0.15% rise in Nifty 50 index and 0.72% gain in Nifty Pharma index. A combined 2.89 million shares changed hands on the counter on BSE and NSE so far.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in